THE DIFFERENCE OF SERUM CARBOXY-TERMINAL PROPEPTIDE OF PROCOLLAGEN TYPE I (PIP) IN STAGE A, B AND C HEART FAILURE PATIENTS CAUSED BY HYPERTENSION

Nurul Aini

doi:10.22146/acta interna.3848

THE DIFFERENCE OF SERUM CARBOXY-TERMINAL PROPEPTIDE OF PROCOLLAGEN TYPE I (PIP) IN STAGE A, B AND C HEART FAILURE PATIENTS CAUSED BY HYPERTENSION

https://doi.org/10.22146/acta%20interna.3848

Nurul Aini^(1*)

(1)
(*) Corresponding Author

Abstract

ABSTRACT

Introduction. Arterial hypertension affects the heart tissue composition which leads to structural remodeling of the myocardium. The imbalance between synthesis and degradation of type I collagen leading to myocardial fibrosis in a form of type I collagen fiber accumulation in the interstitial and perivascular myocardium. Collagen fiber accumulation reduces relaxation stage, diastolic suction, myocardial stiffness and diastolic dysfunction which affect systolic dysfunction leading to heart failure. Concentration of carboxy-terminal pro peptide of pro collagen type I (PIP) in peripheral blood am a synthesis index of type I collagen in HHD. Thus, the measurement of PIP is useful to monitor myocardial fibrosis stage in heart failure and to determine the therapeutic strategy that aims not only to reduce arterial pressure and left ventricular mass but also to prevent myocardial remodeling.

Aim of the study. The aim of the study was to ascertain the difference PIP level in patients with the heart failure stage A, B, and C which are caused by hypertension. The serum concentration of PIP was measured by enzyme immunoassay. This research was a cross sectional research designed for cardiology policlinic’s outpatients at Dr. Sardjito General Hospital Yogyakarta from August 2009 until the calculated sample number is fulfilled.

Method. One-way ANOVA was used to analyze the differences between the three groups of heart failure stages after being tested for the normality using Kolmogorov-Smirnov normality test. If the result did not show a normal value, a non-parametric test would be undergone using Kruskal-Wallis test followed by Mann-Whitney U test. The differences considered as significant if p < 0.05 with a confidence interval of 95%.

Result. The research was performed in 64 patients heart failure caused by hypertension consisted of 22 stages A, 19 stage B and 23 stage C. PIP mean levels of the group stage B 819.78 ± 91,03 ng/ml was higher compared stage A 808.47± 80.8 ng/ml and PIP mean level stage C 852 ± 55.51 ng/ml was higher compared stage B. The PIP mean levels did not differ statistically significantly (p=0. 317).

Conclusion. There were no significant differences in serum level of PIP on the stage heart failure A, B and C.

Keywords: Collagen, fibrosis, hypertension, heart failure, carboxy-terminal pro peptide

Full Text:

PDF

References

Chobanian, A.V., Bakris, G.L., Black, H.R., Cushman, W.C.,Green, L.A., Izzo, J.L., et al. The seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure the JNC 7 Report. JAMA: 2003. 289:2560-2572.

IzzoJr, J.L., Gradman, A.H. Mechanisms and management of hypertensive heart disease: from left ventricular hypertrophy to heart failure. MED Clin N Am. 2004. 88:1257–1271.

Querejeta, R., López, B., González, A., Sánchez, E., Larman, M.,Ubago, J.M., Díez, J. Increased Collagen Type I Synthesis in Patients with Heart Failure of Hypertensive Origin Relation to Myocardial Fibrosis Circulation. 2004. 110:1263-1268.

Querejeta, R., Varo, N., ˜a Lo´pez, B., Larman, M., Artin˜ano, E.,Etayo, J.C., et al. Serum Carboxy-Terminal Pro peptide of Pro collagen Type I Is a Marker of Myocardial Fibrosis in Hypertensive Heart Disease. Circulation. 2000. 101:1729-1735.

Soegondo, S. Obesitas. dalam: A.W. Sudoyo., B. Setiyohadi., I. Alwi., M. Simadibrata, K., S. Setiati (editor). Buku Ajar Ilmu Penyakit Dalam, Jilid III, edisi V, Pusat Penerbitan Departemen Ilmu Penyakit Dalam FK-UI, Jakarta. 2009. 1973-1983.

Dangri, P., Agarwal, S., Kaira, O., Rajpal, S. Echocardiographic assessment of left ventricular hypertrophy in patients with chronic renal failure. Indian Journal of Nephrology.2003. 13:92-3.

Selvetella, G., Notte, A., Maffei A., Calistri, V., Scamardella, V. Left ventricular Hypertrophy is Associated With asymptomatic Cerebral Damage in Hypertensive Patients. Stroke.2003; 34:1766-7.8. Hunt, S.A., Abraham, W.T., Chin, M.H., Feldman, A.M.,Francis, G.S., Ganiats, T.G., et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult.Circulation.2005.112:e154-e235.

Vikrant, S., Tiwari, S.C. Essential Hypertension Pathogenesis and Pathophysiology. Journal, Indian Academy of Clinical Medicine. 2001. 2:141- 61.

Chukwuka, U.A., Anayo, O.C., Amaechi, A.J. Evaluation of left ventricular structures in normotensive and hypertensive subjects by two dimensional echocardiography: Anthropometric correlates in hypertension. Internet Journal of Medical Update. 2008. 3:3-7

Díez, J., Frohlich, E.D. A translational Approach to Hypertensive Heart Disease. Hypertension. 2010. 55:1-8.

Richard, M.B., Thomas, K., Begona, L., Magnus, E., Arantxa, G., Javier, D., Et al. Myocardial fibrosis and diastolic dysfunction in patients with hypertension: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SIVHIA). (Abstract) Journal of Hypertension. 2007. 25:1958-1966.

Liang, S., Jinghan, W., Luosha, Z., Taixing, W. Carboxy terminal pro peptide of type I pro collagen and amino terminal pro peptide of type III pro collagen in patients with chronic heart failure. (abstract). Journal of Clinical Cardiology 2004;1

DOI: https://doi.org/10.22146/acta%20interna.3848